Eleni Polyzou
Overview
Explore the profile of Eleni Polyzou including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akinosoglou K, Schinas G, Papageorgiou E, Karampitsakos T, Dimakopoulou V, Polyzou E, et al.
World J Virol
. 2024 Dec;
13(4):96573.
PMID: 39722762
Background: The risk of severe coronavirus disease 2019 (COVID-19) in pregnant women is elevated. Aim: To examine the outcomes of pregnant women with COVID-19 and report perinatal outcomes and complications,...
2.
Polyzou E, Schinas G, Bountouris P, Georgakopoulou D, de Lastic A, Parthymou A, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39595974
The COVID-19 pandemic has prompted interest in identifying reliable biomarkers to predict disease severity and guide clinical decisions. Prolactin (PRL), a hormone traditionally associated with lactation, has gained attention for...
3.
Akinosoglou K, Schinas G, Papageorgiou D, Polyzou E, Massie Z, Ozcelik S, et al.
Diagnostics (Basel)
. 2024 Oct;
14(20).
PMID: 39451635
Background/objectives: Vulvovaginal candidosis (VVC) is a common condition among women, with current diagnostic methods relying on clinical evaluation and laboratory testing. These traditional methods are often limited by the need...
4.
Akinosoglou K, Schinas G, Polyzou E, Tsiakalos A, Donders G
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274376
Vulvovaginal candidosis (VVC) represents a frequent and cumbersome vaginal infection. Recurrent and/or persistent infections remain common among a significant number of patients despite the use of antifungals. Probiotics offer a...
5.
Chandroulis I, Schinas G, de Lastic A, Polyzou E, Tsoupra S, Davoulos C, et al.
Pathogens
. 2024 Aug;
13(8).
PMID: 39204277
Bloodstream infections (BSIs) can be primary or secondary, with significant associated morbidity and mortality. Primary bloodstream infections (BSIs) are defined as infections where no clear infection source is identified, while...
6.
Schinas G, Schinas I, Ntampanlis G, Polyzou E, Gogos C, Akinosoglou K
Life (Basel)
. 2024 Apr;
14(4).
PMID: 38672792
The transformation of HIV into a manageable chronic condition has unveiled new clinical challenges associated with aging-related pathologies, including bone disease. This review explores the intricate relationship between HIV, antiretroviral...
7.
Akinosoglou K, Rigopoulos E, Papageorgiou D, Schinas G, Polyzou E, Dimopoulou E, et al.
J Fungi (Basel)
. 2024 Apr;
10(4).
PMID: 38667949
Amphotericin B (AmB) has long stood as a cornerstone in the treatment of invasive fungal infections (IFIs), especially among immunocompromised patients. However, the landscape of antifungal therapy is evolving. New...
8.
Tsiakalos A, Schinas G, Karatzaferis A, Rigopoulos E, Pappas C, Polyzou E, et al.
Viruses
. 2024 Mar;
16(3).
PMID: 38543828
Primary Epstein-Barr virus (EBV) infection manifests with diverse clinical symptoms, occasionally resulting in severe complications. This scoping review investigates the rare occurrence of acute acalculous cholecystitis (AAC) in the context...
9.
Akinosoglou K, Tsiakalos A, Dimopoulou I, Schinas G, Polyzou E, Kourea-Kremastinou J, et al.
J Antibiot (Tokyo)
. 2023 Nov;
77(2):120-125.
PMID: 38017085
The prevalence of antibiotic-resistant urogenital mycoplasmas and ureaplasmas has been gradually increasing over the years, leading to greater concern for accurate diagnosis and treatment. In this study, the antimicrobial resistance...
10.
Tsiakalos A, Ziakas P, Polyzou E, Schinas G, Akinosoglou K
Microorganisms
. 2023 Aug;
11(8).
PMID: 37630633
Fluvoxamine, a selective serotonin reuptake inhibitor with anti-inflammatory properties, has gained attention as a repurposed drug to treat COVID-19. We aimed to explore the potential benefit of fluvoxamine on outpatients...